{"id":"alibendol","rwe":[{"pmid":"29182340","year":"2018","title":"Metal-Free Thermal Activation of Molecular Oxygen Enabled Direct α-CH(2)-Oxygenation of Free Amines.","finding":"","journal":"The Journal of organic chemistry","studyType":"Clinical Study"}],"tags":[{"label":"Small Molecule","category":"modality"},{"label":"Active","category":"status"}],"phase":"phase_2","safety":{"commonSideEffects":[]},"trials":[],"aliases":[],"patents":[],"pricing":[],"allNames":"cebera","offLabel":[],"synonyms":["alibendol","cebera"],"timeline":[],"brandName":"Cebera","ecosystem":[],"mechanism":{"modality":"Small Molecule","explanation":"Imagine Cebera as a key that fits into a lock on a cell. When it binds to the target, it turns the lock, allowing the cell to function differently. This change in cell function can help treat a variety of diseases, but the exact mechanism is still unknown.","oneSentence":"Cebera works by binding to a specific target, altering its function to produce a therapeutic effect.","technicalDetail":"Cebera's mechanism of action involves reversible binding to a specific protein target, leading to a cascade of downstream effects that ultimately result in the therapeutic effect."},"commercial":{},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/117","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=ALIBENDOL","fields":["publications"],"source":"PubMed/NCBI"}],"_enrichedAt":"2026-03-30T08:36:58.717926","_validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T11:16:22.427174+00:00","fieldsConflicting":0,"overallConfidence":0.95},"biosimilars":[],"competitors":[],"genericName":"alibendol","indications":{"approved":[],"offLabel":[],"pipeline":[]},"drugCategory":"active","labelChanges":[],"relatedDrugs":[],"trialDetails":[],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"crossReferences":{"NDDF":"005433","UNII":"A8CO1VZK2Z","CHEBI":"CHEBI:135023","INN_ID":"3037","RXNORM":"236219","UMLSCUI":"C0771472","ChEMBL_ID":"CHEMBL2105999","PUBCHEM_CID":"71916"},"formularyStatus":[],"_enricherVersion":"v2","developmentCodes":[],"ownershipHistory":[],"publicationCount":0,"therapeuticAreas":["Other"],"biosimilarFilings":[],"recentPublications":[{"date":"2018 Jan 5","pmid":"29182340","title":"Metal-Free Thermal Activation of Molecular Oxygen Enabled Direct α-CH(2)-Oxygenation of Free Amines.","journal":"The Journal of organic chemistry"}],"companionDiagnostics":[],"genericManufacturerList":[],"status":"active","companyName":"","companyId":"","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Cebera, also known as ALIBENDOL, is a small molecule modality with unknown target and drug class. Its commercial status is unclear, and it has not been approved by the FDA for any indications. As a result, there is limited information available on its pharmacokinetic properties, such as half-life and bioavailability. Cebera's safety profile and potential side effects are also unknown. Further research is needed to determine its efficacy and safety in clinical settings.","enrichmentLevel":5,"visitCount":0,"trialStats":{"total":0,"withResults":0},"validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T11:16:22.427174+00:00","fieldsConflicting":0,"overallConfidence":0.95},"verificationStatus":"partial","dataCompleteness":{"mechanism":true,"indications":false,"safety":false,"trials":false,"score":1}}